What cancers are the main indications for enzalutamide/enzalutamide?

Enzalutamide/Enzalutamide ( Enzalutamide) is an androgen receptor inhibitor, mainly used to treat prostate cancer that is closely related to the androgen signaling pathway. Its indications cover patients with prostate cancer at various stages, including castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer with a high risk of metastasis after biochemical recurrence.

First, castration-resistant prostate cancer is a condition in which prostate cancer cells continue to grow and spread despite castration treatment. Such patients are often resistant to traditional hormonal therapy, and tumor progression complicates clinical treatment. Enzalutamide inhibits the activity of androgen receptors through multiple mechanisms. It not only prevents androgens from binding to the receptors, but also interferes with the nuclear transport and downstream signaling of the receptors, thereby effectively delaying the progression of the disease and improving the survival and quality of life of patients.

Secondly, enzalutamide is also suitable for patients with metastatic castration-sensitive prostate cancer, whose tumors are still sensitive to castration therapy but are at risk of metastasis. At this stage, the use of enzalutamide can further enhance the anti-tumor effect, help patients control the disease, and reduce the possibility of recurrence. Studies show that combining enzalutamide with other standard treatments can help improve the overall effectiveness of treatment.

Finally, enzalutamide is also indicated for patients with non-metastatic castration-sensitive prostate cancer who are at high risk of metastasis after biochemical recurrence. Although these patients currently have no clear symptoms of metastasis, their biochemical indicators (such as prostate-specific antigen, PSA) show an increasing trend, indicating that there may be a potential risk of metastasis. Through early use of enzalutamide, active intervention can be performed when the tumor is still in a non-metastatic state, reducing the risk of future metastasis and improving long-term prognosis.

Reference materials:https://www.xtandi.com/